FDA Contests Court Intervention On Plan B As Teva Argues For Exclusivity

In CRR’s lawsuit, FDA and Teva argue that the firm’s potential for OTC market exclusivity for Plan B One-Step should be protected. But while Teva is open to judicial intervention on whether to allow universal OTC sales, FDA says precedent supports judicial deference to agency scientific decisions.